Back to results
US 12,377,118 B2Granted
Nanoparticle constructs for systemic co-delivery of anti-tumor agents
AssigneeCase Western Reserve University
InventorsEfstathios Karathanasis, Prabhani Atukorale, Wyatt Becicka, Peter Bielecki
Life of this patent
Estimating the term…
Abstract
An immuno-nanoparticle construct for use in therapeutic applications includes a nanocarrier, a stimulator of interferon (IFN) genes (STING) pathway agonist, and a toll-like receptor 4 (TLR4) agonist, wherein the STING pathway agonist and the TLR4 agonist are co-loaded in the nanoparticle carrier.
Claims27
An immuno-nanoparticle construct for systemic administration comprising:
- a nanoparticle carrier;
- a (STING) pathway agonist;
- and
- a (TLR4) agonist, wherein the STING pathway agonist and the TLR4 agonists are co-loaded into the nanoparticle carrier.
1 more element
A method of treating cancer in a subject, the method comprising:
- administering systemically to the subject a therapeutically effective amount of an immuno-nanoparticle construct, the construct including a nanoparticle carrier, a STING pathway agonist, and a TLR4 agonist, wherein the STING pathway agonist and the TLR4 agonist are co-loaded in the nanoparticle carrier, and wherein the STING pathway agonist and the TLR4 agonist synergize to generate a greater amount of Type 1 interferon β in the subject compared to administration of either agent alone.
An immuno-nanoparticle construct for systemic administration comprising:
- a nanoparticle carrier, wherein the nanoparticle carrier includes a mesoporous silica nanocore and an external lipid bilayer coated around the nanocore;
- a (STING) pathway agonist;
- and
- a (TLR4) agonist, wherein the STING pathway agonist is encapsulated within the nanocore of the nanoparticle carrier and wherein the TLR4 agonist is incorporated within the lipid bilayer of the nanoparticle carrier.
1 more element
Dependencies are inferred from the claim text.